MLS Bio Appoints James LaFlamme as Chair of the Board

MLS Bio is delighted to announce the appointment of US Based, James LaFlamme, RPh, MS, FACHE, as Chair of the Board, bringing more than three decades of global leadership in healthcare, pharmaceuticals, regulatory affairs, and commercial strategy.

Mr LaFlamme is a distinguished healthcare executive and pharmacist whose career has spanned clinical practice, regulatory strategy, and business leadership. He is the founder and former Chief Executive Officer of BioPharma Global, where he led international advisory services supporting drug developers in rare and underserved conditions, culminating in the company’s acquisition by Pace Analytical Life Sciences.

His previous roles include Executive Vice President at Coté Orphan, where he directed regulatory and business development strategy, senior leadership at the National Committee for Quality Assurance (NCQA) overseeing accreditation and recognition programs, and healthcare advisory leadership at PwC’s Public Sector Healthcare Advisory practice. He currently serves on the Dean’s Advisory Board at the UConn School of Pharmacy and is a Fellow of the American College of Healthcare Executives.

“James LaFlamme’s appointment as Chair marks an exciting new chapter for MLS Bio,” said Professor Albert Frauman, Founder and Medical Director. “His extensive global experience across regulatory, clinical, and commercial landscapes will be invaluable as we advance our oncology and antiviral pipeline and prepare for entry into international markets. James brings both vision and executional expertise that will strengthen our governance and sharpen our global strategy.”

Mr LaFlamme’s leadership will support MLS Bio’s mission to develop breakthrough small-molecule therapeutics addressing urgent unmet needs in oncology and infectious disease while positioning the company for ongoing commercialisation of its innovative therapeutic pipeline.